The global HER2-positive gastric cancer market is currently valued at USD 1261.8 Million in 2023 and is anticipated to expand at a CAGR of 3.5%. Owing to the technological advances in healthcare the market is likely to propel to USD1779.8 Million by 2033.
The increase in disease burden and approval of pipeline candidates are likely to drive the growth of the HER2 positive market in the forecast period.
| Report Attribute | Details |
|---|---|
| Expected Market Value (2023) | USD 1261.8 Million |
| Projected Forecast Value (2033) | USD 1779.8 Million |
| Global Growth Rate (2023 to 2033) | 3.5% CAGR |
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
The HER2-positive gastric cancer market is expected to gain market growth in the forecast period of 2023 to 2033. Latest market analysis by FMI the market is to grow at a CAGR of 3.5% in the above-mentioned forecast period.
The stomach cancer cells have too much of a growth-promoting protein called HER2 on their surface. Cancers with increased levels of HER2 are called HER2-positive. Drugs that target the HER2 protein can often be helpful in treating these cancers.
Over the coming years, the soaring emphasis on the development of more effective treatment procedures and advanced drugs is projected to foster the HER2-positive gastric cancer market.
The Approval of New Targeted and Immunotherapy Drugs Is Expected to Fuel the Market Growth During the Forecast Period
The increasing incidence of adenocarcinoma, lymphoma, and gastrointestinal stromal tumors across the globe. Major drivers for the stomach cancer market are treatment advancements, combination therapies, an increasing number of cancer treatment centers
Quick approvals from the regulatory authorities regarding HER2-positive gastric cancer drugs may bring immense growth prospects for the gastric cancer drugs market. Research and development activities play an important role in developing novel drugs and therapies.
For instance, in January 2021, the USA FDA approved Enhertu, an antibody-drug conjugate product for treating HER-2-positive metastatic gastric cancers.
Increasing Healthcare Awareness to Boost the Market Growth
Health awareness amongst the population is rising which results in the prediction of drugs boosting the market growth. The innovative launches in medications for treating HER 2-positive gastric cancer are expected to prompt the market simultaneously.
Different researchers are investing in launching drugs that benefit the market. This creates more opportunities in the market. An increase in the incidence of gastrointestinal tumors, lymphoma, and adenocarcinoma; a rise in alcohol consumption, a surge in smoking, and an increase in the geriatric population are anticipated to boost the growth of the global HER 2 positive gastric cancer testing market during the forecast period.
Principal Consultant
Stringent Government Regulation for Drug Approval May Restrain The Market Growth
Despite a positive growth trajectory, the global HER2-positive Gastric Cancer market is facing various challenges that are likely to pose a threat to its growth during the forecast period.
The lack of understanding of intratumoral heterogeneity, erosion in innovator sales, like the launch of biosimilars, and lack of universal guidelines for the assessment of HER2 overexpression or amplification may restrain the growth of the market during the forecast period.
The lack of adequate financial assistance from health insurance policies and stringent regulatory procedures for approving the complex nature of radiation devices are the major factors that can hamper the gastric cancer market growth over the forecast period.
Increasing cancer cases in the region drive the market growth in North America
North America dominated the market and accounted for the largest revenue share of around 3.4% in 2023. The rising prevalence of gastric cancer is driving the growth of the HER2-positive gastric cancer market in North America.
Gastric cancer is the third leading cause of cancer mortality with a five-year survival rate of 5% for metastatic disease.1,2 Approximately one in five gastric cancers are considered HER2 positive. An estimated 27,600 new cases of gastric cancer will be diagnosed this year and the disease could lead to more than 11,000 deaths in the USA in 2020.
Thus, the increasing number of gastric cancer cases in the region is expected to rise the demand for effective therapies for treating patients with gastric cancer which in turn is anticipated to fuel the market growth over the forecast period.
The rising adoption of targeted cancer therapy and the availability of advanced technology in cancer research and treatment centers boost the market growth in the region.
For instance, in May 2020 AstraZeneca and Daiichi Sankyo Company, Limited has been granted Orphan Drug Designation (ODD) in the USA for the treatment of patients with gastric cancer, including gastroesophageal junction cancer.
Increase in Significant Research and Development Investments in Healthcare to Boost the Market Growth
Europe is estimated to witness considerable growth during the forecast period due to increasing investments in the development of advanced treatment options and the rising target patient population.
Furthermore, the rising company activities in conducting clinical trials for developing effective drugs for patients suffering from HER2-positive gastric cancer as well as increasing product launches and approvals in the region are expected to fuel the market growth.
For instance, AstraZeneca and Daiichi Sankyo’s Enhertu (trastuzumab deruxtecan) has been approved in the European Union (EU) as monotherapy for the treatment of adult patients with advanced HER2-positive gastric or gastroesophageal junction (GEJ) adenocarcinoma who have received a prior trastuzumab-based regimen.
Advancement in Healthcare to Propel the Market Growth
Asia Pacific is anticipated to expand at the fastest CAGR of % during the forecast period. Rapid growth in global demand for drugs has encouraged major drug manufacturers to set up facilities for manufacturing Research and Development in this region. Initiatives undertaken by various organizations to create awareness, educate people, and raise funds for the disease are anticipated to propel regional growth.
Furthermore, advancements in healthcare infrastructure, rising government spending on healthcare policies, and the presence of important members in Asia Pacific all contribute to the growth of the global HER2-positive gastric cancer market.
Country-wise Forecast CAGRs for the HER2 Positive Gastric Cancer Market
| The UK | 3.3% |
|---|---|
| India | 3.1% |
| South Korea | 3.3% |
| China | 3.2 % |
| The USA | 3.4 % |
Get the data you need at a Fraction of the cost
Personalize your report by choosing insights you need
and save 40%!
Targeted Therapy Segment remains dominant among other types
Based on the therapy, the targeted therapy accounted for the largest market share in 2023. This is attributed to the increased adoption of targeted therapy along with the chemotherapy and rise in awareness regarding combination therapies for gastric cancer. HER-2 inhibitor trastuzumab is the only molecular targeted drug approved by the USA Food and Drug Administration (FDA) for the first-line treatment of HER-2-positive advanced gastric cancer. The segment held a revenue share of over 55.4% in 2023
Therefore, the rising prevalence of gastric cancer and increased usage of targeted therapy in combination with different other therapies has fostered the growth of this segment in the past few years.
Immunotherapy is estimated to be the fastest-growing segment during the forecast period. The rising awareness among patients regarding the effectiveness and benefits of immunotherapy over chemotherapy is expected to boost the growth of this segment. The growing focus of the manufacturers and the active participation of the authorities like the FDA and EMA in the approval of immunotherapy drugs is expected to augment the demand for immunotherapy drugs for the treatment of Her2-positive gastric cancer.
Hospital and Speciality Clinics Dominated the Market
The Hospital and speciality clinics segment dominated the Her 2 positive gastric cancer therapy market in 2023 with a revenue share of over 35.0%. Initiatives by regional governments to develop healthcare infrastructure is expected to drive the segment growth during the forecast period. Based on the end-user, the market has been segmented into hospitals and speciality and ambulatory surgery centres.
The ambulatory surgery centre segment accounted for the second-largest share in 2021. Most patients with gastric cancer undergo inpatient administration of treatment in developing nations. This is one of the major factors fueling the growth of this segment.
How do New Entrants Contribute to the HER2 Positive Gastric Cancer Market?
With technological innovations happening at a rapid pace, and companies looking for ways to increase customer engagement, start-ups are taking all possible steps to establish a name for themselves in the HER2-positive Gastric Cancer market.
Some of the start-ups in the HER2-positive Gastric Cancer market include-
Key pharmaceutical companies that are working efficiently in the HER2-positive Gastric Cancer space include names like AstraZeneca, Bayer, Bristol-Myers Squibb, Hutchison Medipharma, LintonPharm, Shanghai Henlius Biotech, Sanofi, Pfizer, Novartis AG, and others.
The manufacturers are involved in the production of HER2-positive Gastric Cancer in a larger capacity. Research and innovation are also conducted to launch innovative products for HER2-positive Gastric Cancer.
Also, some of the key players are acquiring small pharmaceutical companies to increase their production capacity. Suppliers are focusing on expanding their market presence across the world by initiating new product launches and boosting sales.
| Report Attribute | Details |
|---|---|
| Growth Rate | CAGR from 2023 to 2033 |
| Expected Market Value (2023) | USD1261.8 Million |
| ProjectedForecast Value (2033) | USD1779.8 Million |
| Base Year for Estimation | 2022 |
| Historical Data | 2017 to 2022 |
| Forecast Period | 2023 to 2033 |
| Quantitative Units | Revenue in USD Million & CAGR from 2023 to 2033 |
| Report Coverage | Revenue Forecast, Volume Forecast, Company Ranking, Competitive L&scape, Growth Factors, Trends & Pricing Analysis |
| Segments Covered | Therapy, Stage, End-user, Regions |
| Regions Covered | North America; Latin America; Western Europe; Eastern Europe; Asia-Pacific; Middle East & Africa (MEA) |
| Key Countries Profiled | The USA, Canada, Brazil, Mexico, Benelux, France, Germany, Italy, Nordic, Spain, The UK, Poland, Russia, India, Malesia, Singapore, Thailand, Australia, New Zealand, GCC, South Africa, Israel |
| Key Companies Profiled | AstraZeneca; Bayer; Bristol-Myers Squibb; Ono Pharmaceutical Co. Ltd; Hutchison Medipharma; LintonPharm; Shanghai Henlius Biotech; Sanofi; Pfizer; Novartis AG |
| Customization | Available Upon Request |
The global Her 2 positive gastric cancer market is likely to reach a valuation of USD 1261.8 Million by the end of 2023.
AstraZeneca, Bayer, Bristol-Myers Squibb, Hutchison Medipharma, LintonPharm are some of the key players in the global HER2 positive gastric cancer market
Sales of HER2 positive gastric cancer market are likely to expand at 3.5% CAGR through 2033.
The US, Canada, Japan, China, & Germany are expected to drive most of the demand for HER2 positive gastric cancer market.
By the end of 2033, the global market for HER2-positive gastric cancer market is predicted to reach a valuation of USD1779.8 Million
1. Executive Summary | HER2 Positive Gastric Cancer Market 2. Market Overview 3. Market Background 4. Global Market Analysis 2018 to 2022 and Forecast, 2023 to 2033 5. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Therapy 5.1. Chemotherapy 5.2. Immunotherapy 5.3. Radiation Therapy 5.4. Targeted Therapy 5.5. Surgery 6. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Stage 6.1. Stage I 6.2. Stage II 6.3. Stage III 6.4. Stage IV 7. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By End User 7.1. Ambulatory Surgery Centers 7.2. Hospitals and Specialty Clinics 7.3. Others 8. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Region 8.1. North America 8.2. Latin America 8.3. Western Europe 8.4. Eastern Europe 8.5. Asia-Pacific 8.6. Middle East & Africa (MEA) 9. North America Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 10. Latin America Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 11. Western Europe Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 12. Eastern Europe Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 13. APAC Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 14. MEA Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 15. Key Countries Market Analysis 16. Market Structure Analysis 17. Competition Analysis 17.1. AstraZeneca 17.2. Bayer 17.3. Bristol-Myers Squibb 17.4. Ono Pharmaceutical Co. Ltd 17.5. Hutchison Medipharma 17.6. LintonPharm 17.7. Shanghai Henlius Biotech 17.8. Sanofi 17.9. Pfizer 17.10. Novartis AG 18. Assumptions & Acronyms Used 19. Research Methodology
Explore Healthcare Insights
View Reports
HER2 Positive Gastric Cancer Market
